Adalimumab
Articles · Refrigerated Storage · Lactation Safety Information · New Medicines · Published , updated
Articles
RMOC briefing on adalimumab – July 2019
This sixth briefing paper is provided through the RMOC system. It is the July edition of a series of briefings on best value biological medicines.… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resourcesAdalimumab: procurement and reference pricing FAQ
See below for an FAQ document produced through the RMOC system on adalimumab. It includes detail on the procurement process, its outcome and implementation. Adalimumab Biosimilar medicine RMOC medicines optimisation recommendations and resourcesUpdate on development of biosimilar versions of adalimumab with particular focus on excipients and injection site reactions
An overview of the five versions of adalimumab currently available in the UK. These article focuses on the differences in excipients and in particular the… Acute Care AdalimumabRMOC briefing on adalimumab – December
This fifth briefing paper is provided through the RMOC system. It is the December edition of a series of briefings on best value biological medicines.… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resourcesRCN and NHS England briefing on best value biological medicines for specialist nurses
NHS England has worked in partnership with the Royal College of Nursing (RCN) to produce a briefing for specialist nurses on best value biological medicines,… Adalimumab Biosimilar medicine RMOC medicines optimisation recommendations and resources RMOC recommendations and resourcesAdalimumab barriers to uptake: results of national survey
NHS England commissioned NHS Commissioning Support Units as a collaborative to develop and complete a survey of a sample of NHS Trusts to identify the… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resourcesAdalimumab toolkit for commissioners and providers
The Commissioning Support Units have produced an interactive toolkit and associated resources on behalf of (and approved by) the Regional Medicines Optimisation Committees. These resources… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resourcesAdalimumab press release
NHS England has published a press release in relation to the availability of adalimumab which is available here. Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resourcesRMOC briefing on adalimumab – October 2018
This fourth briefing paper is provided through the RMOC system. It forms the October edition of a series of briefings on best value biological medicines.… Adalimumab Biosimilar medicine News RMOC medicines optimisation recommendations and resources RMOC recommendations and resourcesAdalimumab commissioning intentions
This document builds upon NHS England’s commissioning intentions for biological medicines published in September 2017. It sets out the tendering strategy for adalimumab in particular,… Adalimumab News RMOC recommendations and resourcesRefrigerated Storage
Humira · AbbVie
In the event of an inadvertent temperature excursion the following data may be used:
A single Humira pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not used within the 14 -day period
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
For information outside of this excursion, contact AbbVie Ltd directly. Refer to the current BNF for company contact details.
Amgevita · Amgen Ltd
In the event of an inadvertent temperature excursion the following data may be used:
The pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The pre-filled syringe or pre-filled pen must be protected from light, and discarded if not used within the 14-day period.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Imraldi · Biogen
Once exposed to temperatures up to 25°C, the syringe or pen must be used within 28 days or discarded, even if it is returned to the refrigerator.
You should record the date when the syringe or pen is first removed from refrigerator, and the date after which it should be discarded.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Hyrimoz · Sandoz
In the event of an inadvertent temperature excursion the following data may be used:
A single Hyrimoz pre-filled syringe / pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The pre-filled syringe / pre-filled pen must be protected from light, and discarded if not used within the 14-day period.
The manufacturers have stated that they will deal with temperature excursions on a case by case basis to ensure the most up to date information is provided each time. Refer to the current BNF for company contact details.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
Hulio · Mylan
In the event of an inadvertent temperature excursion the following data may be used:
A single Hulio pre-filled syringe or pre-filled pen may be stored at temperatures up to a maximum of 25°C for a period of up to 14 days. The syringe or pen must be protected from light, and discarded if not used within the 14 -day period.
Please also refer to the manufacturer’s product literature for recommended storage information at https://www.medicines.org.uk
For information outside of this excursion, contact Mylan directly. Refer to the current BNF for company contact details.